You are here

Structural & Congenital Heart Disease

 

The self-expanding Centera transcatheter heart valve has received CE mark approval, device manufacturer Edwards Lifesciences announced Feb. 15.

Survivors of childhood heart defects are more likely than the general population to develop dementia, including at earlier ages, researchers reported Feb. 12 in Circulation.

US News & World Report issued their rankings for the top 10 hospitals for pediatric cardiology and heart surgery in the country.

New research published in the Journal of the American Medical Association suggests a patent foramen ovale (PFO), colloquially known as a hole in the heart, can double the risk of stroke within 30 days of non-cardiac surgery.

The LOTUS Edge Aortic Valve System will not be available in Europe or the U.S. until at least 2019, Boston Scientific CEO Mike Mahoney said during a Feb. 1 conference call with investors.

 

Recent Headlines

Edwards’ Centera TAVR valve gains CE mark

The self-expanding Centera transcatheter heart valve has received CE mark approval, device manufacturer Edwards Lifesciences announced Feb. 15.

Congenital heart disease survivors more likely to develop early dementia

Survivors of childhood heart defects are more likely than the general population to develop dementia, including at earlier ages, researchers reported Feb. 12 in Circulation.

Texas Children's ranked No. 1 hospital for pediatric cardiology, heart surgery

US News & World Report issued their rankings for the top 10 hospitals for pediatric cardiology and heart surgery in the country.

A hole in the heart may increase the risk of stroke after non-cardiac surgery

New research published in the Journal of the American Medical Association suggests a patent foramen ovale (PFO), colloquially known as a hole in the heart, can double the risk of stroke within 30 days of non-cardiac surgery.

Boston Scientific’s LOTUS valves off the market until at least 2019

The LOTUS Edge Aortic Valve System will not be available in Europe or the U.S. until at least 2019, Boston Scientific CEO Mike Mahoney said during a Feb. 1 conference call with investors.

TAVR valves drive sales growth for Edwards Lifesciences

Edwards Lifesciences reported on Feb. 1 fourth-quarter 2017 sales of $888.5 million, a 16 percent growth year over year. The increase was largely driven by the success of the Transcatheter Heart Valve Therapy division, which brought in $519.3 million in revenue for the quarter

Baseline depression linked to poorer outcomes in TAVR, SAVR

Symptoms of depression are widespread among elderly patients undergoing aortic valve replacement (AVR) surgery, and the condition is associated with as much as a threefold increase in mortality risk a year after the procedure, researchers reported in JAMA Cardiology this week.

Researchers ID predictors of next-day discharge after ‘minimalist’ TAVR

Next-day discharge after minimalist transcatheter aortic valve replacement (TAVR) was safe for patients who didn’t experience perioperative complications and was linked to better one-year outcomes versus patients discharged later, according to a single-center study published in JACC: Cardiovascular Interventions.

AHA's 2017 overhaul of valvular heart disease guidelines, broken down

The American Heart Association (AHA) and American College of Cardiology (ACC) rolled out new guidelines for managing valvular heart disease (VHD) in 2017, marking the second overhaul of VHD recommendations in three years—a move attributable to “extensive new data” that have shaped the way clinicians treat valve disease.

New-generation device, better sizing eliminates TAVR survival disparity between sexes

A larger valve option and more appropriate valve sizing using preprocedural imaging may eliminate the previously reported survival disparity between men and women undergoing transcatheter aortic valve replacement (TAVR), a new study in JACC: Cardiovascular Interventions suggests.

Pages